Cibus, Inc. (CBUS)
Materials · Agricultural Biotechnology · NASDAQ
Cibus is an agricultural biotechnology company that uses precision gene editing to help seed companies create higher-yielding, more resilient crops faster than traditional breeding.
What Cibus, Inc. does
Cibus is an agricultural biotechnology company that uses its proprietary Rapid Trait Development System (RTDS) gene-editing platform to develop specific genetic traits in crops. By precisely modifying a plant's own genes without adding foreign DNA, Cibus creates crops with improved productivity, herbicide tolerance, and disease resistance, which are licensed to seed companies for royalty payments. Additionally, the company is developing sustainable ingredients, such as bio-based fragrances and oils, using yeast fermentation and gene-edited crops.
Recent developments
In August 2026, Cibus expanded its letter of intent with partner Interoc to include the development of five Rice traits instead of two. The company also implemented workforce reductions in March 2026 as part of a streamlining effort to reduce annual net cash usage to approximately $30 million or less.
From Cibus, Inc.'s filing of 2026-08-13.
Themes: gene editing / CRISPR, sustainable agriculture, crop yield improvement, industrial biotechnology, bio-based ingredients, ag-tech licensing
Fundamentals
- Price$1.39 as of 2026-10-20 close
- Market cap$106M as of 2026-08-07 (share count; price 2026-10-20)
- 1-year return-16.3% 2025-10-20 close $1.66 → 2026-10-20 close $1.39
- P/En/a negative earnings
- Net margin-3492.3% FY2025, SEC XBRL
- Gross margin+100.0% FY2022, SEC XBRL
- ROE-582.2% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.06 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)-14.6% FY2025, SEC XBRL
- Revenue CAGR (3y)+185.1% SEC XBRL
- Beta1.81 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CBUS compares in its sector
- net profit marginbottom 10% 125 covered Materials peers, as of 2026-09-03
- operating marginbottom 10% 108 covered Materials peers, as of 2026-09-03
- gross margintop 10% 92 covered Materials peers, as of 2026-09-03
- return on equitybottom 10% 144 covered Materials peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 127 covered Materials peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 122 covered Materials peers, as of FY2025
Position among covered Materials companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which CBUS reported a dividend payment is FY2015, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2015 ratio would not describe CBUS today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2015) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $994000 | -$13M | -$22M | -$0.29 | -$9M† | -$42000† |
| Q1 FY2026 2026-03-31 | $2M | -$12M | -$21M | -$0.33 | -$11M | $115000 |
| Q4 FY2025 2025-12-31 | $1M† | -$23M† | -$31M† | -$0.57† | -$13M† | $86000† |
| Q3 FY2025 2025-09-30 | $615000 | -$15M | -$24M | -$0.44 | -$12M† | $108000† |
| Q2 FY2025 2025-06-30 | $933000 | -$18M | -$25M | -$0.61 | -$14M† | $93000† |
| Q1 FY2025 2025-03-31 | $1M | -$42M | -$47M | -$1.34 | -$12M | $291000 |
| Q4 FY2024 2024-12-31 | $1M† | -$18M† | -$23M† | -$0.50† | -$14M† | $56000† |
| Q3 FY2024 2024-09-30 | $2M | -$200M | -$180M | -$7.63 | -$14M† | $355000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$20M
- Total debt$865000 borrowings only; leases excluded
- Net debt-$20M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Cibus, Inc. looks technically
Cibus, Inc. (CBUS) is trading 26.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 98 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day low about 4 trading days ago. It is 66.8% below its highest point of the past year. Trading volume is unusually light — only about 48% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 26.2% below its 200-day average, the long-term trend line — a long-term downtrend | -26.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.59 | $1.59 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.88 | $1.88 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 98 trading days ago — a "death cross", a bearish long-term signal | 98 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 22.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30) | 41.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.26 to $1.77) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 25.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.19 | $4.19 |
|---|---|---|
| From the 52-week high | it is 66.8% below its 52-week high (its highest price of the past year) | -66.8% |
| Above the 52-week low | it is 27.5% above its 52-week low (its lowest price of the past year) | +27.5% |
| Below the 52-week high | it is 66.8% below its highest point of the past year | 66.8% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $1594.50 (set on 2017-10-11) | $1594.50 |
| Given back of the 52-week move | over the past year its closes ranged ($1.16 to $4.05), and it has given back almost all of its rise from last year’s low — 92% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.17 to $2.26. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 92.0% |
| From the all-time high | it is 99.9% below its all-time high | -99.9% |
| Nearest price level | it is trading 0.7% below a resistance level at $1.40 — a price it turned at twice since 2025-04-07, most recently on 2026-09-15. Since 2024-10-21 it has 3 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.7% |
| All-time low | its lowest closing price on record is $1.09 (set on 2025-11-14) | $1.09 |
| Above the all-time low | it is 27.5% above its all-time low | +27.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1225 between its high and its low — about 8.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1225 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.27 and $1.74 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.27 – $1.51 – $1.74 |
| Typical daily range (% of price) | its price moves about 8.8% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.8% |
| Stretch from the 200-day average | it is trading 4.0 daily ranges below its 200-day average price (26.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 48% of its 30-day average | 0.48× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.5% |
|---|---|---|
| Open gap | it gapped 9.0% below the previous close 46 sessions ago and has not traded back through the level it left behind at 1.9 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -8.9% |
| Gap filled | a 2.6% gap down opened on 2026-10-12 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 14.6 percentage points (the stock lost 13.7% while the market gained 1.0%) | -14.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.7 percentage points (the stock lost 21.0% while the market gained 3.6%) | -24.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 19.4 percentage points (the stock lost 10.9% while the market gained 8.5%) | -19.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 30.8 percentage points (the stock lost 16.3% while the market gained 14.6%) | -30.8% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 19.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -16.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.09 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -33.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.61 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -13.8% |
Price levels it has turned at before
CBUS last closed at $1.39 on 2026-10-20. Since 2024-10-21 it has turned at 3 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.40 | Resistance | 0.7% above the last close | turned there twice · 2025-04-07 to 2026-09-15 |
| $1.35 | Support | 2.8% below the last close | turned there twice · 2025-10-10 to 2026-09-29 |
| $1.46 | Resistance | 5.0% above the last close | turned there twice · 2025-09-19 to 2026-01-21 |
| $1.51 | Resistance | 8.5% above the last close | turned there four times · 2025-06-05 to 2026-09-02 |
| $1.27 | Support | 8.8% below the last close | turned there twice · 2025-09-30 to 2026-04-29 |
| $1.21 | Support | 12.9% below the last close | turned there three times · 2025-08-21 to 2026-05-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$14.33 range $2.00 – $25.00; median $16.00
Analyst estimates, as of 2026-10-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CBUS
- Consensus EPS estimate-$0.175 next reporting period, as of 2026-10-21
- Estimate change, 30 days$0.00 from -$0.175, on 2026-09-16, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy dependence on the successful commercialization of Rice herbicide tolerance traits and sustainable fragrance ingredients to generate significant revenue.","Substantial financial losses and historical unprofitability requiring ongoing cost-containment measures and potential future capital raises.","Regulatory environment volatility despite current favorable trends for gene-edited, non-transgenic crops."]
What changed in the latest 10-Q
AI-assisted comparison of CBUS's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing includes an extended Overview and Business Update narrative describing plant breeding timelines, GMO regulatory costs and timelines, Cibus's gene editing approach, trait development system, crop platforms, patents, and favorable regulatory treatment with specific country examples.
- Newer filing states the European Union adopted rules for New Genomic Techniques under 'its 2026 rules on NGTs'.
- Newer filing includes a Business update through the second quarter of 2026 rather than only the first quarter of 2026.
- Newer filing states Cibus 'completed a leadership transition' during the second quarter of 2026.
- Newer filing states Rice field trials of an improved first-generation trait occurred during the second quarter of 2026 and that work identified specific genetic changes responsible for herbicide tolerance and fertility.
- Newer filing states testing of traits transferred to Interoc in May 2026 is underway, which if successful would support an initial launch of Interoc's enhanced seed products in Latin America.
- Newer filing states that in August 2026, Cibus and Interoc amended their letter of intent to expand contemplated scope from two Rice traits to five, providing for development of three additional traits and their potential commercialization, and that parties continue to negotiate a definitive agreement.
- Newer filing provides details on Cibus's seven Rice seed-company customers across Latin America and the United States with an approximately $200.0 million annual addressable royalty opportunity across a combined estimated 5-7 million peak addressable acres.
- Newer filing states Cibus is continuing discussions with additional seed companies in Latin America and India.
- Newer filing updates initial launch targets for Rice herbicide tolerance: initial launch in Latin America beginning in 2028 with expansion into the United States in 2029, and attributes this update to a strategic focus on hybrid varieties with greater long-term strategic value.
- Newer filing states the Sustainable Ingredients program is in a commercial ramp-up phase with a consumer-products partner for its initial biofragrance product.
- Newer filing states Cibus began receiving payments for pre-commercial scale up materials in the fourth quarter of 2025.
- Removed:
- Older filing states Cibus's Rice HT program continues a targeted initial launch in Latin America beginning in 2027, with expansion planned into the United States in 2029.
- Older filing states the decision to delay the United States target launch date from the previous 2028 target relates to aspects of the registration process for the Rice herbicide of Cibus's chemistry partner, Albaugh, which are behind initial timing estimates.
- Older filing states that in April, the Council of the European Union confirmed the agreed legislative text regulating New Genomic Techniques with that text now before the European Parliament for a plenary vote planned for an upcoming session.
- Older filing includes accumulated deficit of $879.5 million as of March 31, 2026, net loss of $21.2 million for the three months ended March 31, 2026, and expectation of significant expenses and operating losses for the next several years.
- Older filing includes a Results of Operations section for the three months ended March 31, 2026 compared to March 31, 2025 with a summary results table and detailed line-item analysis including revenue, R&D expense, SG&A expense, goodwill impairment, royalty liability interest expense, other interest income, non-operating income, and net loss attributable to noncontrolling interest.
- Older filing states sustainable ingredients program execution of an amendment to its current contract enabling additional partner-funded R&D activities.
- Reworded:
- Newer filing replaces the Older filing's shorter company description ('leading agricultural biotechnology company...') with a longer technology-focused description including plant breeding timelines, GMO regulatory pathway costs, and Cibus's approach of editing a plant's own genes without adding foreign DNA.
- Newer filing describes operational crop platforms as Rice, Canola and Winter Oilseed Rape, Flax, and Cassava, with additional crop platforms including Soybean in development; this platform-specific detail is not present in the Older filing's MD&A text provided.
- Newer filing changes the Rice herbicide tolerance initial launch timeline from Latin America beginning in 2027 to Latin America beginning in 2028.
- Newer filing removes the reference to Albaugh registration process timing as the reason for the U.S. launch delay that was present in the Older filing.
- Newer filing replaces the Older filing's European Union regulatory update (April Council confirmation and upcoming European Parliament plenary vote) with a statement that the European Union adopted NGT rules under its 2026 rules on NGTs.
- Newer filing adds a statement that Cibus is updating its initial launch targets in Latin America with a strategic focus on hybrid varieties; this rationale was not present in the Older filing.
- Notes:
- The newer filing text is truncated mid-sentence in the Sustainable Ingredients section after 'Cibus'.
- The older filing text is truncated mid-sentence in the Liquidity and Capital Resources section after 'cash and cash equivalents, with a'.
- The newer filing text is truncated before any Results of Operations or Liquidity discussion, so those sections cannot be compared if present in the full filing.
- The older filing text appears to begin with an Overview and Business Update that is substantially shorter than the newer filing's corresponding section, which may reflect a reorganization of content between periods.
Risk Factors
- Reworded:
- The newer filing (2026-08-13) changed the balance sheet date from March 31, 2026 to June 30, 2026.
- The newer filing (2026-08-13) changed the statements of operations and comprehensive loss from a three-month period ended March 31, 2026 to three-month and six-month periods ended June 30, 2026.
- The newer filing (2026-08-13) changed the stockholders' equity rollforward period from the three months ended March 31, 2026 to the three months ended June 30, 2026.
- The newer filing (2026-08-13) updated financial statement figures in the balance sheet, statements of operations, comprehensive loss, and stockholders' equity to reflect the June 30, 2026 period.
- Notes:
- The provided texts contain the Risk Factors narrative plus subsequent financial statement pages; the Risk Factors narrative itself appears identical between the two filings.
- Only the financial statement sections following the Risk Factors narrative show changes between the filings, and these may be outside the intended Risk Factors section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CBUS — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CBUS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,325,944
- Reported value $16,886,544
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CBUS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CBUS had 3,316,848 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for CBUS because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 3,316,848
- Prior settlement (shares) 3,450,826
- Reported change -3.88%
- Days to cover (reported) 25.84
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bayer CropScience (BAYRY)
- Corteva (CTVA)
- Syngenta
- BASF (BASFY)
- Pairwise
- Elo Life Systems
- Ginkgo Bioworks (DNA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CBUS vs…
Frequently asked questions
What does Cibus, Inc. (CBUS) do?
Cibus is an agricultural biotechnology company that uses its proprietary Rapid Trait Development System (RTDS) gene-editing platform to develop specific genetic traits in crops. By precisely modifying a plant's own genes without adding foreign DNA, Cibus creates crops with improved productivity, herbicide tolerance, and disease resistance, which are licensed to seed companies for royalty payments.
What sector is Cibus, Inc. (CBUS) in?
Cibus, Inc. (CBUS) is classified in the Materials sector. Its industry is Agricultural Biotechnology. It trades on NASDAQ.
Who are Cibus, Inc.'s (CBUS) competitors?
Notable peers of Cibus, Inc. (CBUS) include Bayer CropScience, Corteva, Syngenta, BASF and Pairwise. This peer set is informational only — not financial advice.
Is Cibus, Inc. (CBUS) overbought or oversold right now?
Cibus, Inc. (CBUS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 41, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CBUS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.